PIPAC with Nal-IRI
Phase 1Small molecule
PIPAC with Nal-IRI is one of 7 small molecule programs targeting Peritoneal Carcinomatosis. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Peritoneal Carcinomatosis
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 2
Adrucil
EElorac, Inc.
Phase 2
Abraxane
Bristol-Myers SquibbPhase 1
Mitomycin C
GGynecologic Oncology Group
Phase 2
PIPAC with Nal-IRI
UUniversity Hospital, Ghent
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PIPAC with Nal-IRI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity Hospital, Ghent